A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 3, 2026

Study Completion Date

February 18, 2027

Conditions
Alzheimer's Disease
Interventions
DRUG

E2814

E2814 IV infusion.

DRUG

Lecanemab

Lecanemab SC injection.

DRUG

Placebo

Placebo IV infusion.

Trial Locations (28)

19001

Abington Neurological Associates Ltd, Abington

23294

National Clinical Research-Richmond, Inc, Richmond

31909

Columbus Memory Center, PC, Columbus

32127

Progressive Medical Research, Port Orange

32159

Charter Research, Lady Lake

33135

Advanced Clinical Research Network, Miami

33414

Alzheimer's Research and Treatment Center, Wellington

33609

Axiom Brain Health, Tampa

34205

Bradenton Research Center, Bradenton

34470

Renstar Medical Research, Ocala

34711

K2 Medical Research, Clermont

34997

Alzheimer's Research and Treatment Center, Stuart

38018

Neurology Clinical, P.C., Cordova

39401

Memory Center/Hattiesburg Clinic, Hattiesburg

63110

Washington University School of Medicine, St Louis

85351

Banner Sun Health Research Institute, Sun City

1730015

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo

2118533

Nippon Medical School Hospital, Kanagawa

9900834

Yamagata Tokushukai Hospital, Yamagata

06510

Yale University School of Medicine, New Haven

75231-4350

Kerwin Medical Center, Dallas

474-8511

National Center for Geriatrics and Gerontology, Ōbu

739-0696

National Hospital Organization Hiroshima-Nishi Medical Center, Ōtake

880-1111

Keimei Memorial Hospital, Higashimorokatagun

710-0813

Rijikai Medical Corporation Katayama Medical Clinic, Kurashiki

545-8586

Osaka Metropolitan University Hospital, Osaka

160-0023

Tokyo Medical University Hospital, Tokyo

160-8582

Keio University Hospital, Tokyo

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT06602258 - A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter